Company History

Formed in Calgary Alberta, Canada in 2017, the company’s intellectual property emerged from important research discoveries that were made at the University of Ottawa Heart Institute and the Libin Cardiovascular Institute at the University of Calgary. Pemi31 Therapeutics owns the IP and is an independent company.

Leadership

Pemi31 was co-founded by Ed O’Brien, MD (cardiologist and researcher; below left) and Michelle Gagnon, PhD (population health and knowledge translation expert; below centre). Joe Tucker, PhD (experienced pharmaceutical executive; below right) is based in Boston and leads the business enterprise.